ONCY
Oncolytics Biotech Inc.1.0400
+0.1170+12.7%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
111.91MP/E (TTM)
-Basic EPS (TTM)
-0.29Dividend Yield
0%Recent Filings
8-K
Launches REO 033 colorectal trial
Oncolytics Biotech launched REO 033, a randomized Phase 2 study on March 2, 2026, testing pelareorep plus bevacizumab and FOLFIRI versus control in 2L RAS-mutant MSS mCRC patients, powered for ORR with 30 patients per arm. Prior REO 022 data showed 27-month median OS and 33% ORR, trouncing standard care's 11.2 months and 10%. Sites start this month. Preliminary data due year-end.
8-K
Pivots to anal, colorectal registration
Oncolytics Biotech concluded enrollment in the GOBLET gastrointestinal cancer study on February 24, 2026, pivoting resources to registrational studies in squamous cell anal cancer and metastatic colorectal cancer. GOBLET Cohort 4 showed promising efficacy in second-line SCAC, supporting a single-arm U.S. trial under 100 patients; Cohort 5 PDAC enrollment halts at ~20 patients per arm. Cash on hand funds near-term milestones without immediate dilution. FDA meeting set for mid-April.
8-K
FDA Fast Track for pelareorep
Oncolytics Biotech secured FDA Fast Track Designation on February 4, 2026, for pelareorep combined with bevacizumab and FOLFIRI in second-line KRAS-mutant MSS metastatic colorectal cancer. Data showed 33% ORR, 16.6-month PFS, and 27-month OS—doubling or tripling standard-of-care benchmarks. A controlled study launches soon. Interim data due year-end.
8-K
Oncolytics appoints key execs
Oncolytics Biotech appointed John McAdory as EVP of Strategy and Operations and Yujun Wu as VP, Head of Biostatistics, on January 14, 2026, to bolster late-stage clinical execution in pancreatic, colorectal, and anal cancer programs. Both bring proven oncology trial expertise from CG Oncology and Morphic Therapeutic. Inducement awards: McAdory got 500,000 stock options and 300,000 RSUs; Wu, 300,000 options—all at $0.97 strike. Leadership bolsters regulatory push.
8-K
Shareholders approve Nevada domestication
Oncolytics Biotech shareholders approved on January 15, 2026, a two-step move from Alberta to British Columbia, then to Nevada, plus the 2026 Incentive Award Plan, with votes exceeding 76% for each. Resolutions passed handily: 85% for continuance, 87% for domestication. This streamlines regulatory and operational processes. Expected to close by end of Q1 2026.
IPO
Employees
Sector
Industry
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
CGON
CG Oncology, Inc.
37.85-1.90
CRDF
Cardiff Oncology, Inc.
2.40-0.01
CYDY
CytoDyn Inc.
0.32+0.02
OKUR
OnKure Therapeutics, Inc.
3.02-0.18
OLMA
Olema Pharmaceuticals, Inc.
34.28-1.55
ONC
BeOne Medicines Ltd.
304.31-6.36
ONCO
Onconetix, Inc.
1.94-0.04
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
REPL
Replimune Group, Inc.
9.61-0.34